NCT06076239: ESWT

Effect of Extracorporeal Shock Wave Therapy in Impingement Syndrome

Completed NA Last updated 10 October 2023

What this trial tests

NA trial testing ESWT Group in Shoulder Impingement Syndrome in 32 participants. Completed in 30 June 2022.

Timeline

3 March 2022

Primary endpoint
24 June 2022

30 June 2022

Quick facts

Lead sponsor	Istanbul Arel University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	32
Start date	3 March 2022
Primary completion	24 June 2022
Estimated completion	30 June 2022
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

• ESWT Group
• Control Group — full drug profile →

Conditions studied

• Shoulder Impingement Syndrome — all drugs for Shoulder Impingement Syndrome →
• Trigger Point Pain — all drugs for Trigger Point Pain →

Sponsor

Istanbul Arel University

Who can join

Adults 18 to 70, any sex, with Shoulder Impingement Syndrome or Trigger Point Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose: This study aimed to investigate the effectiveness of ESWT applied to trigger points on pain, function, and effusion in individuals diagnosed with shoulder impingement syndrome.

Material and methods: This was a randomized controlled clinical trial with a total of 32 which were randomly divided into two equal groups (ESWT Group (EG), n = 16; Control Group (CG), n=16). The participants in the EG were given Extracorporeal Shock Wave Therapy to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles for a total of 5 sessions in 3 weeks (2 sessions in the first week, 2 sessions in the second week, 1 session in the third week) in addition to conventional treatment while CG received only conventional treatments for five days per week for 3 consecutive weeks. The primary outcome was pain intensity Visual analog scale (VAS). Secondary measurements were Tendon thickness and effusion with Ultrasound, Range of motion (ROM), Manual muscle testing (MMT), Corbin posture analysis, Constant Murley Score (CMS), Arm Shoulder and Hand Problems Questionnaire (DASH). Supraspinatus tendon thickness and effusion of the cases included in the study were evaluated by ultrasonography before and after the treatment(3 weeks) by the same specialist physician who was blind to the groups. Normal joint range of motion by universal goniometer, muscle strength by manual muscle test, posture evaluation by Corbin posture analysis, pain evaluation by Visual Analogue Scale (VAS), functional evaluation by Constant Murley Score (CMS), Arm Shoulder and Hand Problems Questionnaire (DASH) by physiotherapist It was evaluated before and after the treatment (3 weeks).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.